Immunis is a private biotechnology company researching and developing secretome products to address age-driven immune deficits. Our investigational secretome product, IMMUNA, leverages our leading-edge capabilities in cell culture to deliver a product of all natural, all human immune modulators in their natural relative concentrations. Immunis is currently testing the effects of IMMUNA in a Phase 1/2a clinical trial for muscle atrophy.